Minimal_JJ
residual_JJ
disease_NN
in_IN
acute_JJ
myelogenous_JJ
leukemia_NN
with_IN
PML\/RAR_NN
alpha_NN
or_CC
AML1\/ETO_NN
mRNA_NN
and_CC
phenotypic_JJ
analysis_NN
of_IN
possible_JJ
T_NN
and_CC
natural_JJ
killer_NN
cells_NNS
in_IN
bone_NN
marrow_NN
._.

Here_RB
we_PRP
studied_VBD
minimal_JJ
residual_JJ
disease_NN
-LRB-_-LRB-
MRD_NN
-RRB-_-RRB-
of_IN
patients_NNS
with_IN
acute_JJ
myeloid_JJ
leukemia_NN
-LRB-_-LRB-
AML_NN
-RRB-_-RRB-
who_WP
have_VBP
PML\/RAR_NN
alpha_NN
or_CC
AML1\/ETO_NN
as_RB
well_RB
as_IN
the_DT
phenotypic_JJ
analysis_NN
of_IN
lymphocyte_NN
subsets_NNS
involved_VBN
in_IN
antitumor_JJ
immunity_NN
._.

Eight_CD
patients_NNS
in_IN
long-term_JJ
-LRB-_-LRB-
LT_NN
;_:
3_CD
to_TO
15_CD
years_NNS
-RRB-_-RRB-
and_CC
15_CD
patients_NNS
in_IN
short-term_JJ
-LRB-_-LRB-
ST_JJ
;_:
up_RB
to_TO
3_CD
years_NNS
-RRB-_-RRB-
remission_NN
were_VBD
studied_VBN
._.

Using_VBG
the_DT
reverse_JJ
transcription-polymerase_JJ
chain_NN
reaction_NN
-LRB-_-LRB-
RT_NN
-RRB-_-RRB-
assay_NN
,_,
the_DT
limit_NN
of_IN
detection_NN
was_VBD
10_CD
-LRB-_-LRB-
-5_CD
-RRB-_-RRB-
to_TO
10_CD
-LRB-_-LRB-
-6_CD
-RRB-_-RRB-
for_IN
PML\/RAR_NN
alpha_NN
transcript_NN
and_CC
10_CD
-LRB-_-LRB-
-4_CD
-RRB-_-RRB-
to_TO
10_CD
-LRB-_-LRB-
-5_CD
-RRB-_-RRB-
for_IN
the_DT
AML1\/ETO_NN
transcript_NN
._.

Simultaneously_RB
,_,
T_NN
lymphocyte_NN
subsets_NNS
and_CC
NK_NN
cells_NNS
from_IN
the_DT
peripheral_JJ
blood_NN
-LRB-_-LRB-
PB_NN
-RRB-_-RRB-
and_CC
bone_NN
marrow_NN
-LRB-_-LRB-
BM_NN
-RRB-_-RRB-
were_VBD
investigated_VBN
by_IN
flow_NN
cytometric_JJ
analysis_NN
._.

Four_CD
of_IN
the_DT
eight_CD
patients_NNS
in_IN
LT_NN
and_CC
7_CD
of_IN
the_DT
15_CD
patients_NNS
in_IN
ST_JJ
remission_NN
were_VBD
MRD-positive_JJ
._.

Although_IN
all_DT
MRD-positive_JJ
patients_NNS
in_IN
LT_NN
remission_NN
are_VBP
still_RB
until_IN
now_RB
event-free_RB
,_,
3_CD
of_IN
the_DT
7_CD
MRD-positive_JJ
-LRB-_-LRB-
MRD_NN
+_NN
-RRB-_-RRB-
patients_NNS
in_IN
ST_JJ
remission_NN
soon_RB
relapsed_VBD
._.

The_DT
total_JJ
populations_NNS
of_IN
CD4_NN
+_NN
,_,
CD8_NN
+_CC
and_CC
CD56_NN
+_NN
-LCB-_-LRB-
possible_JJ
T-cell_NN
and_CC
natural_JJ
killer_NN
-LRB-_-LRB-
T\/NK_NN
-RRB-_-RRB-
populations_NNS
-RCB-_-RRB-
in_IN
the_DT
BM_NN
of_IN
ST_JJ
patients_NNS
and_CC
MRD_NN
+_NN
\/_:
LT_JJ
patients_NNS
were_VBD
significantly_RB
-LRB-_-LRB-
p_NN
&lt;_JJR
.01_CD
-RRB-_-RRB-
low_JJ
._.

The_DT
CD8_NN
+_CC
CD28_NN
+_CC
population_NN
showed_VBD
the_DT
same_JJ
tendency_NN
-LRB-_-LRB-
p_NN
&lt;_JJR
.01_CD
-.02_CD
-RRB-_-RRB-
._.

The_DT
T\/NK_NN
subsets_NNS
in_IN
the_DT
BM_NN
of_IN
MRD-negative_JJ
-LRB-_-LRB-
MRD_NN
-_NN
-RRB-_-RRB-
LT_NN
-LRB-_-LRB-
MRD_NN
-_:
\/_:
LT_NN
-RRB-_-RRB-
patients_NNS
showed_VBD
similar_JJ
numbers_NNS
of_IN
cells_NNS
as_IN
normal_JJ
volunteers_NNS
._.

Basically_RB
,_,
the_DT
total_JJ
percentage_NN
of_IN
the_DT
CD4_NN
+_NN
,_,
CD8_NN
+_NN
and_CC
CD56_NN
+_CC
cell_NN
populations_NNS
in_IN
the_DT
BM_NNS
was_VBD
increased_VBN
and_CC
in_IN
the_DT
following_VBG
order_NN
:_:
MRD_NN
-_:
\/_:
LT_JJ
patients_NNS
,_,
normal_JJ
volunteers_NNS
,_,
MRD_NN
+_CC
\/_NN
LT_NN
patients_NNS
and_CC
MRD_NN
+_CC
or_CC
-_:
\/_:
ST_JJ
patients_NNS
._.

The_DT
percentages_NNS
of_IN
the_DT
T\/NK-cell_JJ
subsets_NNS
in_IN
the_DT
PB_NN
were_VBD
not_RB
significantly_RB
different_JJ
among_IN
these_DT
groups_NNS
._.

Thus_RB
,_,
the_DT
difference_NN
of_IN
the_DT
possible_JJ
T\/NK-cell_JJ
phenotype_NN
in_IN
the_DT
BM_NNS
may_MD
strongly_RB
influence_VB
clinical_JJ
and_CC
molecular_JJ
remission_NN
._.

These_DT
results_NNS
still_RB
remain_VBP
to_TO
be_VB
confirmed_VBN
by_IN
further_JJ
studies_NNS
of_IN
the_DT
functional_JJ
anti-tumor_JJ
immunity_NN
of_IN
T\/NK_NN
cells_NNS
of_IN
AML_NN
in_IN
remission_NN
._.

